November 24, 2015 : DCMS #268

DISASTERS AVERTED — Near Miss Case Studies

Don’t Be So Quick to Stop a Treatment That’s Working

HOMERUN SLIDES — Great Clinical Presentation Highlights

The Present and Future of Insulin Therapy Part 17

CLINICAL GEMS — The Best from Diabetes Texts

Practical Diabetes Care, 3rd Ed., Excerpt #39: Psychological Aspects of Diabetes Part 3 of 4

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Dr. Larry Hirsch, Part 4: Infusion Set Comparison

MOST POPULAR ARTICLES OF THE MONTH

#1 With Injection Techniques, Seeing is Teaching
#2 Ingenuities, Advancements, and Future Endeavors in the Treatment of Diabetes
#3 The Present and Future of Insulin Therapy Part 14

When you do the math, 95% of all diabetes patients have type 2. This does not mean that we should ignore type 1 patients when looking at psychological problems; in fact, most of the information on these problems deals with type 1 patients. These problems can include development of diabetes, medication adherence, and the desire for overall control of the patient’s diabetes. This week our Clinical text looks at the psychological aspects of diabetes and how we as practitioners can take advantage of the current knowledge to improve patient care.

Good examples of the benefit of using these techniques are in both our Disaster Averted for the week and our Top Read article of the month on injection techniques.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief

Man, 52 years of age, type 2 diabetes, obesity class II on Victoza. He was very pleased with treatment response, lowering glucose levels, feeling full and more satisfied, but having a skin reaction.

In this week’s Homerun Slides, the results of lowering plasma glucose concentration with dapagliflozin.

Much of the literature concerns the important problem of type 2 diabetes and depression and, in comparison with type 1 diabetes, little about the psychological disturbances associated with specific phases of type 2 diabetes.

Diabetes in Control publisher Steve Freed met with Dr. Larry Hirsch, Vice President of Global Medical Affairs for the Diabetes Care Business at BD at the 2015 ADA Sessions in Boston. In this final installment, Dr. Hirsch summarizes his ADA 2015 presentation, including a comparison of the BD infusion set to the current popular model, and images showing the fluid within infusion sets as captured by MRI and ultrasound.

I asked a patient with erratic glucose levels where he usually gave his insulin injections to which he responded, “In my arms.” I asked, “Could you show me where?” The patient promptly rolled up his sleeves and pointed to the vein in his antecubital space.

Researchers approximate that 387 million people worldwide are living with diabetes mellitus, whose prevalence will reach 10% of the world’s adult population (592 million) by 2035.

In this week’s Homerun Slides, the effectiveness of Lixisenatide when added to basal insulin, and strategies for avoiding or minimizing the GI effects of GLP-1.